← Back to Search

Lifestyle Changes for Cancer (LCBH Trial)

N/A
Waitlist Available
Led By Dana Bovbjerg, PhD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
History of histologically confirmed bladder cancer (non-metastatic) or colorectal adenoma
Under clinical surveillance with no evidence of disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up blood samples will be collected as part of the 12 month assessment (as feasible)
Awards & highlights

LCBH Trial Summary

This trial will test whether a diet and exercise intervention can prevent telomeres from shortenings in people who have had bladder cancer or colorectal adenoma.

Who is the study for?
This trial is for individuals who have been treated for non-metastatic bladder cancer or colorectal adenoma, with a BMI of 25 to <40. They should not have had any other cancers (except non-melanoma skin cancer) in the past 5 years, no severe high blood pressure, psychiatric treatments, recent significant weight loss or conditions that affect body weight like diabetes.Check my eligibility
What is being tested?
The study tests if a combined diet and exercise program can help improve the length of leukocyte telomere (part of your cells that are linked to aging) in patients with histories of bladder cancer or colorectal adenomas compared to just a diet intervention.See study design
What are the potential side effects?
Since this trial involves lifestyle changes such as dietary adjustments and increased physical activity rather than medication, side effects may include muscle soreness from exercise and potential dietary adjustment discomfort.

LCBH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a confirmed history of bladder cancer or colorectal adenoma.
Select...
My cancer is currently not detectable under medical observation.

LCBH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~blood samples will be collected as part of the 12 month assessment (as feasible)
This trial's timeline: 3 weeks for screening, Varies for treatment, and blood samples will be collected as part of the 12 month assessment (as feasible) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Leukocyte telomere length (LTL) at the 6 month assessment (controlling for appropriate covariates)
Secondary outcome measures
8-OHdG level at 3 months (controlling for appropriate covariates)
8-OHdG level at 6 months (controlling for appropriate covariates)
Glutathione
+12 more
Other outcome measures
Body Mass Index (BMI) at 3 months (controlling for appropriate covariates)
Body Mass Index (BMI) at 6 months (controlling for appropriate covariates)
Body composition at 3 months (controlling for appropriate covariates)
+21 more

LCBH Trial Design

2Treatment groups
Active Control
Group I: DIETActive Control1 Intervention
This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant.
Group II: DIET-PAActive Control2 Interventions
This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant. In addition, this group will be prescribed moderate-intensity Physical Activity Intervention that will progressively increase to the goal of 250 minutes/week.

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,712 Previous Clinical Trials
16,346,403 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,638 Total Patients Enrolled
Dana Bovbjerg, PhDPrincipal InvestigatorUniversity of Pittsburgh
2 Previous Clinical Trials
546 Total Patients Enrolled

Media Library

Dietary Intervention Clinical Trial Eligibility Overview. Trial Name: NCT03286699 — N/A
Telomere Shortening Research Study Groups: DIET, DIET-PA
Telomere Shortening Clinical Trial 2023: Dietary Intervention Highlights & Side Effects. Trial Name: NCT03286699 — N/A
Dietary Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT03286699 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals being enrolled in this investigation at the moment?

"This investigation is no longer accepting participants, as confirmed by the data on clinicaltrials.gov; it was initially posted June 1st 2017 and most recently amended on February 2nd 2022. However, 297 other medical trials are currently enrolling patients for their research endeavours."

Answered by AI

Does the enrollment criteria for this experiment extend to those over 35 years old?

"Per the guidelines of this medical trial, individuals must be between 18 and 84 years old to qualify for enrollment."

Answered by AI

Is it feasible to become a participant in this research?

"This medical study will involve 8 people with telomere shortening, aged 18 to 84. Other requirements are a BMI of 25.0-40 kg/m2, a previous diagnosis of bladder cancer or colorectal adenoma (non-metastatic) and regular clinical checks to ensure no evidence of disease is present."

Answered by AI
~1 spots leftby Mar 2025